Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded
Article excerpt
Highlighted: the sentence this signal was extracted from
Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER 1 and business earnings per share (EPS) 2 of €3.55 Pipeline update Guidance upgraded Belén Garijo, Chief Executive Officer: "Sanofi achieved another strong quarter with double-digit sales growth of 14.3%, mainly driven by our new medicines and Dupixent. Business EPS increased by 19.6%, driven by cost discipline. The pipeline milestones included two regulatory approvals, one regulatory submission, and two additional regulatory designations. Our strong commercial and financial momentum to date leads us to raise our 2026 guidance: sales growth is now expected at a low-teens percentage and business EPS growth at a mid-teens percentage, underscoring our sustainable, profitable growth. In the third quarter, we accelerated Sanofi's transformation by expanding our long-standing alliance with Regeneron, which opens up further opportunities in immunology. We also continued to simplify our portfolio through a partnership with Cheplapharm covering a number of legacy medicines 4 . We are confident about our ability to pursue our strong commercial and financial performance in the short and medium term. The whole organisation is focused on managing Sanofi's post-Dupixent trajectory over the next decade. Our priority is to protect earnings through Dupixent's...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.